Latest ovarian cancer Stories

The pelvic exam, a standard part of a woman's gynecologic checkup, frequently is performed for reasons that are medically unjustified, according to the authors of a UCSF study that may lay the groundwork for future changes to medical practice. The research shows that many physicians mistakenly believe the exam is important in screening for ovarian cancer. The study, which surveyed obstetricians and gynecologists around the country, also shows that doctors continue to perform the exam in...

RALEIGH, N.C., Dec. 14, 2012 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world. NCC has pledged to increase its commitment to assist underserved women's cancer patients at-risk of breast, cervical or ovarian cancers. Helping over 10,000 women in their battle against cancer last year, the Coalition is transforming the lives of underserved women around the globe. "We have built a solid foundation...

Lee Rannals for redOrbit.com – Your Universe Online A common diabetes medication could help in preventing or treating ovarian cancer, according to research published in the journal CANCER. The study found that ovarian cancer patients who took the drug tended to live longer than those patients who did not take it. Previous research showed that metformin, which originated from the French Lilac plant, might have anticancer properties. In the new study, the researchers analyzed...

Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the University of Michigan (U-M) recently discovered that while concern about the recurrence of breast cancer is a major issue for women, most patients who have double mastectomies do not need them. In particular, the team of investigators stated that, of the women who had both breasts removed, 70 percent had only low risk of developing cancer in their healthy breast. The findings from the Michigan...

AUSTIN, Texas, Nov. 28, 2012 /PRNewswire/ -- Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1® which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer. Vermillion, Inc. (NASDAQ: VRML), the molecular diagnostics company which developed and currently markets the test, had reported positive top-line results of the study...

Reintroducing miR-200c to triple-negative breast cancer cells makes migrating cells self-destruct Epithelial cells are homebodies – they like to attach to things and becoming detached initiates a form of cell suicide known as anoikis (literally "homeless" in Latin). But in order for cancer cells to metastasize they have to leave their homes and to survive while traveling they must resist anoikis – like a third-grader at sleep-away camp. Cancer cells do this by taking a page from the...

SAN DIEGO and LOS GATOS, Calif., Nov. 15, 2012 /PRNewswire/ -- The Clearity Foundation (Clearity) and Annai Systems today announced the implementation of a software-driven system (the MedTrust Evidence Engine-E2) that supports Clearity's mission to individualize treatment options for ovarian cancer patients. As a result, Clearity is now more efficiently integrating and interpreting data from many sources, including its Diane Barton Database of more than 250 tumor profiles, enabling...

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) EntreMed reported a net loss for the third quarter of 2012 of ($1.2 million), or ($0.05) per share. This compares with a net loss of ($1.3 million), or...

-PI3-kinase inhibitors sensitized tumors to PARP inhibitors. -Combination significantly prolonged progression-free survival in mouse model. The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research. Triple-negative breast cancers...

AUSTIN, Texas, Nov. 12, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported financial and operational results for the third quarter ended September 30, 2012. Q3 2012 Operational Highlights In Q3, the volume of OVA1®, the company's flagship diagnostic test designed to help differentiate benign from malignant ovarian masses, was in line with management's forecast at approximately 4,100 tests. Submitted a manuscript on the OVA500...